Bilastine as a modern antihistamine for the treatment of allergic rhinitis and urticaria

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Antihistamines have long been an integral part of the treatment of allergic rhinitis and urticaria. Treatment of these diseases is usually long-term, so the drugs of choice are H1-antihistamines of the second generation, which have high efficiency and a good safety profile in the absence of clinically significant side effects. The variety of drugs in this group makes it possible to personalize the therapy, using the drug taking into account the individual sensitivity of the patient. One of the antihistamines used in practical allergy at the present time is bilastine. The article presents the data of clinical studies devoted to the research of the effectiveness, safety and tolerability of Hj-antihistamine of the second generation - bilastine. Short-term and long-term use of bilastine in patients with rhinitis (rhinoconjunctivitis) and chronic urticaria has demonstrated it’s good effectiveness and safety, which are due to the pharmacological properties of the medicine and the peculiarities of its metabolism. A number of sources provide data on the high safety profile of bilastine not only in the standard therapeutic dosage, but also with its four-fold increase. The results of these studies are of particular importance, since the clinical recommendations for the management of urticaria in various countries, including Russia, provide for the possibility of increasing the dose of H1 -antihistamines in case of insufficient effectiveness of therapy. Studies have also shown that bilastine has no clinically pronounced side effects that could significantly limit the use of the medicine, including in patients with concomitant diseases, or negatively affect patient’s compliance. According to the results of clinical studies, bilastine is characterized as an effective, safe, well-tolerated medicine for long-term therapy of allergic rhinitis and urticaria.

Restricted Access

Igor S Gushchin

NRC Institute of Immunology FMBA of Russia


Ekaterina N Medunitsyn

NRC Institute of Immunology FMBA of Russia


  1. Данилычева ИВ, Ильина НИ, Лусс ЛВ, Феденко ЕС, Шульженко АЕ. Федеральные клинические рекомендации: Крапивница. Российский Аллергологический Журнал. 2018;15(5):47-62.
  2. Ильина НИ, Курбачёва ОМ, Павлова КС, Польнер СА. Федеральные клинические рекомендации: Аллергический ринит. Российский Аллергологический Журнал. 2017;14(2):47-54.
  3. Brozek JL, Bousquet J, Baena-Cagnani CE et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2017 revision. J Allergy Clin Immunol. 2017;140(4). DOI: 10/1016/j/ jaci.2017.03.050.
  4. Zuberbier T Aberer W, Asero R et al. Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAA-CI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST EAACI, EIAS, EDF, EM-BRN, ESCD, GA2LEN, IAACI, IADVL, JDA, NVvA, MSAI, OGDV, PSA, RAACI, SBD, SFD, SGAI, SGDV, SIAAIC, SIDeMaST, SPDV, TSD, UNBB, UNEV and WAO. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393-1414. DOI: 10.1111/ all.13397.
  5. Okubo K, Gotoh M, Togawa M, Saito A, Ohashi Y Longterm safety and efficacy of bilastine following up to 12 weeks or 52 weeks of treatment in Japanese patients with allergic rhinitis: Results of an open-label trial. Auris Nasus Larynx. 2017;44(3):294-301. doi: 10.1016/j.anl.2016.07.021.
  6. Friedrich Horak, Petra Zieglmayer, Rene Zieglmayer, Patrick Lemell. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflammation research: official journal ofthe European Histamine Research Society. 2009;59(5):391-398. doi: 10.1007/s00011-009-0117-4.
  7. Гущин ИС, Курбачёва ОМ. Лечение круглогодичного аллергического ринита антигистаминными препаратами. Лечащий врач. 2004;8:20-23.
  8. Аллергология и иммунология: национальное руководство. Под ред. Хаитова Р.М., Ильиной Н.И. М.: ГЭО-ТАР-Медиа. 2009:656.
  9. Хаитов МР, Намазова-Баранова ЛС, Чучалин АГ, Дайхес НА, Ильина НИ, Курбачёва ОМ, Agache I, Bachert C, Bedbrook A, Canonica GW Casale T, Cruz AA, Fokkens WJ, Hellings PW, Samolinski B, Bousquet J. ARIA 2016: Современные направления оказания медицинской помощи больным аллергическим ринитом в свете требований прецизионной медицины. Российский Аллергологический Журнал. 2017;14(3):46-54.
  10. Brozek JL, Bousquet J, Baena-Cagnani CE et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2017 revision. J Allergy Clin Immunol. 2017;140(4). DOI: 10/1016/j/ jaci.2017.03.050
  11. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008;63:8-160. doi: 10.1111/j.1398-9995.2007.01620.x.
  12. Cezmi A, Agache I. Global atlas of allergy. European Academy of Allergy and Clinical Immunology. 2014:388.
  13. Wise SK, Lin SY Toskala E. International consensus statement on allergy and rhinology: allergic rhinitis - executive summary. Int Forum Allergy Rhinol. 2018;8:85-107. DOI: 10.1002/ alr.22070.
  14. Orlandi RR, Kingdom TT, Hwang PH et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(7):S22-S209. DOI: 10.1002/ alr.21695.
  15. Аллергология. Федеральные клинические рекомендации. Под ред. Хаитова Р.М., Ильиной Н.И. «ФАРМАРУС ПРИНТ МЕДИА». 2014:126.
  16. Федеральные клинические рекомендации по диагностике и лечению крапивницы. М.: Российская Ассоциация Аллергологов и Клинических Иммунологов. 2015:34.
  17. Recto MT, Gabriel MT, Kulthanan K, Tantilipikorn P Aw DC, Lee TH, Chwen CC, Mutusamy S, Hao NT, Quang VT, Canonica GW Selecting optimal second-generation antihistamines for allergic rhinitis and urticaria in Asia. Clin Mol Allergy. 2017;15:19. doi: 10.1186/s12948-017-0074-3.
  18. Bosma R, van den Bor J, Vischer HF, Labeaga L, Leurs R. The long duration of action of the second generation antihistamine bilastine coincides with its long residence time at the histamine Hj-receptor. Eur J Pharmacol. 2018;5:838:107-111. doi: 10.1016/j.ejphar.2018.09.011.
  19. Antonijoan R, Coimbra J, Garcia-Gea C, Puntes M, Gich I, Campo C, Valiente R, Labeaga L. Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers. Curr Med Res Opin. 2017;33(1):129-136. doi: 10.1016/S1081-1206(10)61429-9.
  20. Yagami A, Furue M, Togawa M, Saito A, Hide M. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases. J Dermatol. 2017;44(4):375-385. doi: 10.1111/1346-8138.13644.
  21. Serra E, CV del Campo, Novak Z, Majorek-Olechowska B, Pulka G, Garcia-Bea A, Labeaga L. Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study. J Dermatolog Treat. 2019;5:1-9. DQI: 10.1080/09546634.2019.1590522.
  22. Krause K, Spohr A, Zuberbier T, Church MK, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy. 2013;68(7):921-928. DQI: 10.1111/all.12171.
  23. Church MK, Tiongco-Recto M, Ridolo E, Erminia R, Novak Z. Bilastine: a lifetime companion for the treatment of allergies. Current Medical Research and Opinion. 2019;13:1-10. DQI: 10.1080/03007995.2019.1681134.
  24. Kawauchi H, Yanai K, Wang DY, Itahashi K, Qkubo K. Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties. Int J Mol Sci. 2019;20(1):213. DQI: 10.3390/ijms20010213.
  25. Demonte A, Guanti MB, Liberati S, Biffi A, Fernando F, Fainello M, Pepe P. Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients. Eur Rev Med Pharmacol Sci. 2018;22(3):820-828. DQI: 10.26355/eurrev_201802_14318.
  26. Фридлянд ДГ, Гущин ИС, Порошина ЮА, Шульженко АЕ. Сравнительное изучение антигистаминной и антиаллергической активности некоторых противогистаминных препаратов. Терапевтический архив. 2002;74(3):67-72.


Abstract - 102

PDF (Russian) - 5




  • There are currently no refbacks.

Copyright (c) 2020 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies